In the final episode, "Long-Term VMS Management and Key Takeaways for Clinical Practice," the panelists explore the critical importance of viewing menopause management as a long-term, patient-centered endeavor rather than a time-limited intervention.
In "Evaluating Newer Non-Hormonal Therapies for VMS," our panel explores the similarities and distinctions between fezolinetant and elinzanetant as NK receptor antagonists, with a focus on how these differences inform clinical decision-making for a patient with inadequate response to MHT.
In "Evaluating Newer Non-Hormonal Therapies for VMS," our panel explores the similarities and distinctions between fezolinetant and elinzanetant as NK receptor antagonists, with a focus on how these differences inform clinical decision-making for a patient with inadequate response to MHT.
In this episode, "Addressing Cognitive Symptoms and Transitioning from MHT to Non-Hormonal Therapy for VMS," two menopause experts explore the clinical and societal burden of cognitive dysfunction in menopausal women, and the decision-making process around transitioning from hormonal to non-hormonal therapy.
This episode, titled "A Case of a 51-Year-Old Woman with VMS and Inadequate Response to MHT," features panelists examining the clinical approach to a patient presenting with persistent moderate to severe VMS following what appears to be an inadequate response to menopause hormone therapy.
Learn how clinicians counsel menopause hormone therapy: debunk WHI myths, set expectations for relief, weigh risks, and refer for heart screening.
Learn how clinicians counsel hesitant patients on menopause hormone therapy—debunk WHI myths, set expectations, and tailor safety with referrals.
Learn how perimenopause shifts heart and clot risks, and why transdermal estrogen plus progesterone may be safer for women with BMI and hypertension.
Learn how clinicians monitor liver safety for new hot-flash therapies and why teamwork improves menopause care during cancer treatment.
Learn how clinicians monitor liver safety for hot-flash therapies and why multidisciplinary teams improve menopause care during cancer treatment.
Learn how elinzanetant eases hot flashes fast, improves sleep, and supports adherence to life-saving endocrine therapy through shared decisions.
Explore nonhormonal menopause relief for breast cancer survivors—sleep-focused strategies, NCCN guidance, and new elinzanetant data.
Severe menopausal hot flashes disrupt sleep in a breast cancer survivor on anastrozole—explore safe, effective nonhormonal options.
Clinicians unpack hot flashes’ real-life toll and compare lifestyle, hormone, nonhormone, and emerging NK3 therapies to tailor menopause relief.
June 9th 2026
